Pyrimidines

Starczak, Marta; Zarakowska, Ewelina; Modrzejewska, Martyna; Dziaman, Tomasz; Szpila, Anna; Linowiecka, Kinga; Guz, Jolanta; Szpotan, Justyna; Gawronski, Maciej; Labejszo, Anna; Liebert, Ariel; Banaszkiewicz, Zbigniew; Klopocka, Maria; Foksinski, Marek; Gackowski, Daniel; Olinski, Ryszard published an article in 2018, the title of the article was In vivo evidence of ascorbate involvement in the generation of epigenetic DNA modifications in leukocytes from patients with colorectal carcinoma, benign adenoma and inflammatory bowel disease.Application of 4433-40-3 And the article contains the following content:

Background: A characteristic feature of malignant cells, such as colorectal cancer cells, is a profound decrease in the level of 5-hydroxymethylcytosine, a product of 5-methylcytosine oxidation by TET enzymes. Recent studies showed that ascorbate may upregulate the activity of TET enzymes in cultured cells and enhance formation of their products in genomic DNA. Methods: The study included four groups of subjects: healthy controls (n = 79), patients with inflammatory bowel disease (IBD, n = 51), adenomatous polyps (n = 67) and colorectal cancer (n = 136). The list of analyzed parameters included (i) leukocyte levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine, a marker of oxidatively modified DNA, determined by means of isotope-dilution automated online two-dimensional ultra-performance liquid chromatog. with tandem mass spectrometry, (ii) expression of TET mRNA measured with RT-qPCR, and (iii) chromatog.-determined plasma concentrations of retinol, alpha-tocopherol and ascorbate. Results: Patients from all groups presented with significantly lower levels of 5-methylcytosine and 5-hydroxymethylcytosine in DNA than the controls. A similar tendency was also observed for 5-hydroxymethyluracil level. Patients with IBD showed the highest levels of 5-formylcytosine and 8-oxo-7,8-dihydro-2′-deoxyguanosine of all study subjects, and individuals with colorectal cancer presented with the lowest concentrations of ascorbate and retinol. A pos. correlation was observed between plasma concentration of ascorbate and levels of two epigenetic modifications, 5-hydroxymethylcytosine and 5-hydroxymethyluracil in leukocyte DNA. Moreover, a significant difference was found in the levels of these modifications in patients whose plasma concentrations of ascorbate were below the lower and above the upper quartile for the control group. Conclusions: These findings suggest that deficiency of ascorbate in the blood may be a marker of its shortage in other tissues, which in turn may correspond to deterioration of DNA methylation-demethylation. These observations may provide a rationale for further research on blood biomarkers of colorectal cancer development. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Application of 4433-40-3

The Article related to ascorbate epigenetics dna modification leukocyte carcinoma inflammatory bowel disease, ascorbate, colon polyp, colorectal cancer, dna demethylation, epigenetic dna modifications, ibd and other aspects.Application of 4433-40-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Qureshi, Wasay Mohiuddin Shaikh; Pratten, Margaret K. published an article in 2018, the title of the article was Chick embryonic cardiomyocyte micromass system for assessing developmental cardiotoxicity of drugs.Product Details of 626-48-2 And the article contains the following content:

Heart is the first mesodermal organ to develop and is sensitive to life-threatening toxic effects of drugs during development. A number of methods have been devised to study developmental cardiotoxic effects of drugs including micromass system. The micromass system involves the culture of primary embryonic cells and reestablishment of tissue system in vitro. In chick embryonic cardiomyocyte micromass system the chick heart cells are cultured in a small volume at a very high cell d. These cells form synchronized contracting foci. Addition of drugs to this system allows us to study the developmental cardiotoxic effects at mol. level. Using appropriate end points and mol. marker or adopting high-throughput screening, this method can further help to identify and avoid the use of cardiotoxic compounds during development. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Product Details of 626-48-2

The Article related to heart cardiomyocyte micromass system developmental cardiotoxicity vpa bpn, cardiomyocytes, chick, connexin43, developmental toxicology, micromass, reactive oxygen species, teratogens and other aspects.Product Details of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 29, 2020, Pritha Rao, T. V.; Kuzminov, Andrei published an article.Recommanded Product: 65-71-4 The title of the article was Exopolysaccharide defects cause hyper-thymineless death in Escherichia coli via massive loss of chromosomal DNA and cell lysis. And the article contained the following:

Thymineless death in Escherichia coli thyA mutants growing in the absence of thymidine (dT) is preceded by a substantial resistance phase, during which the culture titer remains static, as if the chromosome has to accumulate damage before ultimately failing. Significant chromosomal replication and fragmentation during the resistance phase could provide appropriate sources of this damage. Alternatively, the initial chromosomal replication in thymine (T)-starved cells could reflect a considerable endogenous dT source, making the resistance phase a delay of acute starvation, rather than an integral part of thymineless death. Here we identify such a low-mol.-weight (LMW)-dT source as mostly dTDP-glucose and its derivatives, used to synthesize enterobacterial common antigen (ECA). The thyA mutant, in which dTDP-glucose production is blocked by the rfbA rffH mutations, lacks a LMW-dT pool, the initial DNA synthesis during T-starvation and the resistance phase. Remarkably, the thyA mutant that makes dTDP-glucose and initiates ECA synthesis normally yet cannot complete it due to the rffC defect, maintains a regular LMW-dT pool, but cannot recover dTTP from it, and thus suffers T-hyperstarvation, dying precipitously, completely losing chromosomal DNA and eventually lysing, even without chromosomal replication. At the same time, its ECA+thyA parent does not lyse during T-starvation, while both the dramatic killing and chromosomal DNA loss in the ECA-deficient thyA mutants precede cell lysis. We conclude that: (1) the significant pool of dTDP-hexoses delays acute T-starvation; (2) T-starvation destabilizes even nonreplicating chromosomes, while T-hyperstarvation destroys them; and (3) beyond the chromosome, T-hyperstarvation also destabilizes the cell envelope. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to exopolysaccharide thymidine thya mutation chromosome cell lysis escherichia, cell lysis, chromosome fragmentation, chromosome replication, dtdp-glucose, enterobacterial common antigen and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 21, 2021, Kanouni, Toufike; Arnold, Lee D.; Kaldor, Stephen W.; Murphy, Eric A.; Tyhonas, John published a patent.Reference of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine The title of the patent was Preparation of 4-(pyrrolidin-1-yl)quinazoline, 4-(pyrrolidin-1-yl)isoquinoline, and 1-(pyrrolidin-1-yl)phthalazine derivatives as inhibitors of cyclin-dependent kinases. And the patent contained the following:

The title compounds represented by formula I [ring A = (un)substituted heteroaryl selected from pyridine, pyrazine, pyrimidine, quinoline, isoquinoline, quinazoline, pyrazolopyridine, pyrazolopyrimidine, thienopyrimidine, thienopyridine, pyridopyridine, pyridopyrimidine, or triazene; W = selected from a group having the structure Q-Q13; t = 1 or 2; u = 0, 1, or 2; R1, R2, R3 = each independently H or each (un)substituted C1-4 alkyl, or heterocyclyl(alkyl); R4 = H or (un)substituted C1-4 alkyl, or optionally, if R3 = (un)substituted C1-4 and R4 = (un)substituted, then R3 and R4 together join to form a ring; R5, R6 = each independently H, cyano,NH2, halo, or each (un)substituted C1-4 alkyl, C1-4 alkoxy, or C1-4 aminoalkyl; X = N or CH; Y = N, or C-L1-R11; Z = N or C-L2-R7; L1, L2 = each independently a bond, O, or N(R8); R7 = cyano, halo, or each (un)substituted C1-4 alkyl, C3-7 carbocyclyl, carbocyclyl(alkyl), heterocyclyl, heterocyclyl(alkyl); R8, R9, R10 = each independently H or (un)substituted C1-4 alkyl; R11 = H, cyano, halo, NH2, or each (un)substituted C1-4 alkyl, C3-7 carbocyclyl, carbocyclyl(alkyl), heterocyclyl, or heterocyclyl(alkyl)] or pharmaceutically acceptable salts or solvates thereof are prepared The compounds I are inhibitors of cyclin-dependent kinases (CDKs) and are useful for the treatment of cancer, neoplastic disease, or hyperproliferative disorder in human or animal. Thus, tert-Bu (R)-[1-(7-acrylamidoquinazolin-4-yl)pyrrolidin-3-yl]carbamate was stirred with CF3CO2H in CH2Cl2 at room temperature for 3 h to give (R)-N-[4-(3-aminopyrrolidin-1-yl)quinazolin-7-yl]acrylamide trifluoroacetate which was heated with 2-chloro-5-(trifluoromethyl)pyrimidine in the presence of diisopropylethylamine in DMSO at 80° for 30 min under nitrogen and microwave irradiation to give (R)-N-[4-[3-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]pyrrolidin-1-yl]quinazolin-7-yl]acrylamide (II). II showed IC50 of ≤0.10μM against human recombinant CDK12. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Reference of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

The Article related to pyrrolidinylquinazoline pyrrolidinylisoquinoline pyrrolidinylphthalazine preparation inhibitor cyclin dependent kinase, cancer neoplastic disease hyperproliferative disorder treatment and other aspects.Reference of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 5, 2021, Aybastier, Onder; Demir, Cevdet published an article.HPLC of Formula: 4433-40-3 The title of the article was Optimization and validation of ultrasensitive GC-MS/MS method to measure oxidatively induced DNA damage products and role of antioxidants in oxidation mechanism. And the article contained the following:

Oxidation of DNA due to exposure to reactive oxygen species (ROS) is a major source of DNA damage. ROS induced damage to DNA plays an important role in some diseases such as various cancers, aging and neurodegenerative diseases. The detection of DNA oxidation products plays a major role in assessing the mutagenicity potential of specific exposure. The GC-MS/MS method was developed for the ultrasensitive determination of individual DNA damage products. The validation results revealed that the proposed method was reliable and sensitive. Multiple response surface methodol. (MRSM) was used to optimize derivatization conditions of oxidatively DNA base damage products before GC-MS/MS anal. The optimum derivatization conditions were determined as 40 min for derivatization time, 120°C for derivatization temperature and 1.4 for BSTFA/pyridine ratio under nitrogen atm. The effects of thymol, carvacrol and thymoquinone as antioxidants were investigated on oxidative DNA damage. The determination of the oxidatively induced DNA damage products was performed after adding DNA and antioxidants with different concentrations under oxidative stress. Eighteen DNA base damage products were analyzed simultaneously using GC-MS/MS. This study showed a significant decrease in the amount of DNA base damage products when the antioxidants were present in the medium. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).HPLC of Formula: 4433-40-3

The Article related to dna damage derivatization multiple response surface methodol oxidative stress, dna damage, derivatization, gc–ms/ms, multiple response surface methodology, oxidative stress, validation and other aspects.HPLC of Formula: 4433-40-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Akbarzadeh, Marzieh; Bakavoli, Mehdi; Eshghi, Hossein; Shiri, Ali; Azizollahi, Hamid; Mague, Joel T. published an article in 2018, the title of the article was Synthesis of 2-substituted-4-methyl-5,13-dihydropyrimido[4′,5′:5,6][1,4]thiazepino[2,3-b]quinoxaline as a new heterocyclic system.Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

2-Substituted-4-methyl-5,13-dihydropyrimido[4′,5′:5,6][1,4]thiazepino[2,3-b]quinoxalines, e.g., I, were synthesized through cyclocondensation of 2,4-dichloro-5-(chloromethyl)-6-methylpyrimidine with 3-aminoquinoxaline-2-thiol and subsequent substitution by various secondary amines. Regioselective heterocyclization was confirmed by X-ray crystallog. anal. for 4-methyl-2-(pyrrolidin-1-yl)-5,13-dihydropyrimido[4′,5′:5,6][1,4]thiazepino[2,3-b]quinoxaline (I). The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to chloropyrimidinylmethylthio quinoxalinamine heterocyclization, chloropyrimidothiazepinoquinoxaline preparation secondary amine amination, aminopyrimidothiazepinequinoxaline preparation and other aspects.Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 30, 2020, Fujimoto, Yoshiaki; Nakanishi, Ryota; Nukatsuka, Mamoru; Matsuoka, Kazuaki; Ando, Koji; Wakasa, Takeshi; Kitao, Hiroyuki; Oki, Eiji; Maehara, Yoshihiko; Mori, Masaki published an article.Electric Literature of 65-71-4 The title of the article was Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. And the article contained the following:

Trifluridine (FTD) is the active component of the nucleoside chemotherapeutic drug trifluridine/tipiracil (FTD/TPI), which is approved worldwide for the treatment of patients with metastatic gastrointestinal cancer. FTD exerts cytotoxic effects via its incorporation into DNA, but FTD has not been detected in the tumor specimens of patients. The purpose of this study was to detect FTD in tumors resected from metastatic colorectal cancer (mCRC) patients who were administered FTD/TPI. Another purpose was to investigate the turnover rate of FTD in tumors and bone marrow in a mouse model. Tumors and normal tissue specimens were obtained from mCRC patients who were administered FTD/TPI or placebo at Kyushu University Hospital. Tumors and bone marrow were resected from mice with peritoneal dissemination treated with FTD/TPI. To detect and quantitate FTD incorporated into DNA, immunohistochem. staining of paraffin-embedded specimens (IHC-p staining) and slot-blot anal. of DNA purified from these tissues were performed using an anti-BrdU antibody. IHC-p staining of proliferation and apoptosis markers was also performed. FTD was detected in metastatic tumors obtained from mCRC patients who were administered FTD/TPI, but who had discontinued the treatment several weeks before surgery. In a peritoneal dissemination mouse model, FTD was still detected in tumors 13 days after the cessation of FTD/TPI treatment, but had disappeared from bone marrow within 6 days. These results indicate that FTD persists longer in tumors than in bone marrow, which may cause a sustained antitumor effect with tolerable hematotoxicity. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Electric Literature of 65-71-4

The Article related to trifluridine tipiracil metastatic colorectal cancer human, anti-brdu antibody, liver metastasis, peritoneal dissemination, tas-102), trifluridine (ftd), trifluridine/tipiracil (ftd/tpi and other aspects.Electric Literature of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 30, 2021, Kuramochi, Hidekazu; Yamada, Takeshi; Yoshida, Yoichiro; Matsuda, Akihisa; Kamiyama, Hirohiko; Kosugi, Chihiro; Ishibashi, Keiichiro; Fukazawa, Atsuko; Ihara, Keisuke; Sonoda, Hiromichi; Yoshimatsu, Kazuhiko; Yoshida, Hiroshi; Hasegawa, Suguru; Sakamoto, Kazuhiro; Ishida, Hideyuki; Koda, Keiji; TAS CC3 Study Group published an article.Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was The pre-treatment lymphocyte-to-monocyte ratio predicts efficacy in metastatic colorectal cancer treated with TAS-102 and bevacizumab. And the article contained the following:

Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc anal. Receiver operating characteristic curve analyses of the 3 inflammation-based scores vs. DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to tas102 bevacizumab lymphocyte monocyte inflammation colorectal cancer, tas-102, bevacizumab, colorectal cancer, lymphocyte-to-monocyte ratio (lmr), neutrophil-to-lymphocyte ratio (nlr) and other aspects.Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 11, 2007, Harbottle, Gareth W.; Feeder, Neil; Gibson, Karl R.; Glossop, Mel; Maw, Graham N.; Million, William A.; Morel, Florence F.; Osborne, Simon; Poinsard, Cedric published an article.Application In Synthesis of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine The title of the article was Microwave-assisted synthesis of mGluR1 ligands: carbon, nitrogen, and oxygen linked derivatives of pyrido[3,4-d]pyrimidin-4-ylamines. And the article contained the following:

The syntheses of 6-fluoropyrido[3,4-d]pyrimidin-4-ylamine derivatives is reported herein. Methods for generating C-, N-, and O-linked analogs by subsequent nucleophilic aromatic substitution of fluoride with alcs. or amines under microwave irradiation are described. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Application In Synthesis of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

The Article related to pyridopyrimidinylamine mglur1 ligand preparation, fluoropyridopyrimidinylamine amine nucleophilic aromatic substitution, alc fluoropyridopyrimidinylamine nucleophilic aromatic substitution and other aspects.Application In Synthesis of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 15, 2018, Petrov, Konstantin; Zueva, Irina; Kovyazina, Irina; Sedov, Igor; Lushchekina, Sofya; Kharlamova, Alexandra; Lenina, Oksana; Koshkin, Sergei; Shtyrlin, Yurii; Nikolsky, Evgeny; Masson, Patrick published an article.Computed Properties of 626-48-2 The title of the article was C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: Pharmacokinetic and pharmacodynamic studies. And the article contained the following:

C-547, a potent slow-binding inhibitor of acetylcholinesterase (AChE) was i.v. administered to rat (0.05 mg/kg). Pharmacokinetic profiles were determined in blood and different organs: extensor digitorum longus muscle, heart, liver, lungs and kidneys as a function of time. Pharmacokinetics (PK) was studied using non-compartmental and compartmental analyses. A 3-compartment model describes PK in blood. Most of injected C-547 binds to albumin in the bloodstream. The steady-state volume of distribution (3800 mL/kg) is 15 times larger than the distribution volume, indicating a good tissue distribution. C-547 is slowly eliminated (kel = 0.17 h-1; T1/2 = 4 h) from the bloodstream. Effect of C-547 on animal model of myasthenia gravis persists for more than 72 h, even though the drug is not anal. detectable in the blood. A PK/PD model was built to account for such a pharmacodynamical (PD) effect. Long-lasting effect results from micro-PD mechanisms: the slow-binding nature of inhibition, high affinity for AChE and long residence time on target at neuromuscular junction (NMJ). In addition, NMJ spatial constraints i.e. high concentration of AChE in a small volume, and slow diffusion rate of free C-547 out of NMJ, make possible effective rebinding of ligand. Thus, compared to other cholinesterase inhibitors used for palliative treatment of myasthenia gravis, C-547 is the most selective drug, displays a slow pharmacokinetics, and has the longest duration of action. This makes C-547 a promising drug leader for treatment of myasthenia gravis, and a template for development of other drugs against neurol. diseases and for neuroprotection. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Computed Properties of 626-48-2

The Article related to myasthenia gravis c547 pharmacodynamics pharmacokinetics acetylcholinesterase, 6-methyluracil, acetylcholinesterase, binding kinetics, myasthenia gravis, pharmacodynamics, pharmacokinetics and other aspects.Computed Properties of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia